Literature DB >> 17122103

Biological effects of thyrotropin receptor activation on human orbital preadipocytes.

Lei Zhang1, Glynn Baker, Dominika Janus, Carol A Paddon, Dagmar Fuhrer, Marian Ludgate.   

Abstract

PURPOSE: Thyrotropin receptor (TSHR) expression is upregulated in the orbits of patients with Graves ophthalmopathy (GO), most of whom have TSHR-stimulating antibodies. The authors investigated the biological effects of TSHR activation in vitro in adipose tissue, the site of orbital TSHR expression.
METHODS: Activating mutant TSHR (TSHR*) or wild-type (WT) was introduced into human orbital preadipocytes using retroviral vectors. Their proliferation (Coulter counting), basal cAMP accumulation (radioimmunoassay), and spontaneous and peroxisome proliferator-activated receptor (PPARgamma)-induced adipogenesis (quantitative oil red O staining) were assessed and compared with those of nonmodified cells. QRT-PCR was used to measure transcripts of CCAT/enhancer binding protein (C/EBP)beta, PPARgamma, and lipoprotein lipase (LPL; early, intermediate, and late markers of adipogenesis) and for uncoupling protein (UCP)-1 (brown adipose tissue [BAT]).
RESULTS: Expression of TSHR* significantly inhibited the proliferation of preadipocytes and produced an increase in unstimulated cAMP of 200% to 600%. Basal lipid levels were significantly increased in TSHR* (127%-275%) compared with nonmodified (100%) or WT-expressing (104%-187%) cells. This was accompanied by 2- to 10-fold increases in early-intermediate markers and UCP-1 transcripts (2- to 8-fold); LPL was at the limit of detection. In nonmodified cells, adipogenesis produced significant increases in transcripts of all markers, including LPL (approximately 30-fold). This was not the case in TSHR*-expressing cells, which also displayed 67% to 84% reductions in lipid levels.
CONCLUSIONS: TSHR activation stimulates early differentiation (favoring BAT formation?) but renders preadipocytes refractory to PPARgamma-induced adipogenesis. In neither case did lipid-containing vacuoles accumulate, suggesting that terminal stages of differentiation were inhibited.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122103      PMCID: PMC1892592          DOI: 10.1167/iovs.06-0596

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  29 in total

Review 1.  The thyrotropin receptor in thyroid diseases.

Authors:  R Paschke; M Ludgate
Journal:  N Engl J Med       Date:  1997-12-04       Impact factor: 91.245

2.  Thyrotropin receptor transcripts in human adipose tissue.

Authors:  M S Crisp; C Lane; M Halliwell; D Wynford-Thomas; M Ludgate
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

3.  A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism.

Authors:  N de Roux; M Polak; J Couet; J Leger; P Czernichow; E Milgrom; M Misrahi
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

4.  Effect of activating and inactivating mutations of Gs- and Gi2-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes.

Authors:  J O Gordeladze; K E Høvik; J J Merendino; S Hermouet; S Gutkind; D Accili
Journal:  J Cell Biochem       Date:  1997-02       Impact factor: 4.429

Review 5.  Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism.

Authors:  D Führer; P Wonerow; H Willgerodt; R Paschke
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

6.  Functional expression of thyrotropin receptor in differentiated 3T3-L1 cells: a possible model cell line of extrathyroidal expression of thyrotropin receptor.

Authors:  K Haraguchi; H Shimura; L Lin; T Saito; T Endo; T Onaya
Journal:  Biochem Biophys Res Commun       Date:  1996-06-05       Impact factor: 3.575

7.  Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.

Authors:  J E Digby; C T Montague; C P Sewter; L Sanders; W O Wilkison; S O'Rahilly; J B Prins
Journal:  Diabetes       Date:  1998-01       Impact factor: 9.461

8.  Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue.

Authors:  A Feliciello; A Porcellini; I Ciullo; G Bonavolontà; E V Avvedimento; G Fenzi
Journal:  Lancet       Date:  1993-08-07       Impact factor: 79.321

9.  The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.

Authors:  A W Kung; C C Yau; A Cheng
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

10.  Cyclic AMP-mediated control of lipogenic enzyme synthesis during adipose differentiation of 3T3 cells.

Authors:  B M Spiegelman; H Green
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

View more
  29 in total

1.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

Review 2.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

4.  Fat pad-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies.

Authors:  W S Khan; A B Adesida; S R Tew; U G Longo; T E Hardingham
Journal:  Cell Prolif       Date:  2012-01-20       Impact factor: 6.831

Review 5.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

6.  Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro.

Authors:  Robert F Place; Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Br J Pharmacol       Date:  2017-01-27       Impact factor: 8.739

7.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

8.  Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction.

Authors:  Lei Zhang; Timothy Bowen; Fiona Grennan-Jones; Carol Paddon; Peter Giles; Jason Webber; Robert Steadman; Marian Ludgate
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

Review 9.  Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy.

Authors:  Terry J Smith; Chieh Chih Tsai; Mei-Ju Shih; Shanli Tsui; Beiling Chen; Rui Han; Vibha Naik; Chris S King; Chris Press; Shweta Kamat; Robert A Goldberg; Richard P Phipps; Raymond S Douglas; Andrew G Gianoukakis
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

10.  Gsalpha signalling suppresses PPARgamma2 generation and inhibits 3T3L1 adipogenesis.

Authors:  Lei Zhang; Carol Paddon; Mark D Lewis; Fiona Grennan-Jones; Marian Ludgate
Journal:  J Endocrinol       Date:  2009-05-21       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.